A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures
Epilepsia · 2026-02 · 67 (2) · 660-672
DOI: 10.1111/epi.18698 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 27.10.2025. Verfasst von Sang Kun Lee und 20 weiteren Autor:innen. Beteiligte Einrichtung: National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Seizures, Chlorophenols. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SK Biopharmaceuticals, SK Life Science.
Abstract (Originalsprache)
Objectives
This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures.
Methods
Adults 18–70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic–clonic) during an 8‐week baseline, despite treatment with 1–3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18‐week titration phase and a 6‐week maintenance phase. The primary efficacy analysis was a hierarchical step‐down comparison of the percent change from baseline in 28‐day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day.
Results
Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was −25.9% for placebo vs −42.6%, −78.3%, and −100% for cenobamate 100, 200, and 400 mg/day, respectively (all p 's < .001). During the 12‐week period encompassing the last 6 weeks of titration and the 6‐week maintenance phase (secondary outcome), the median percent change in seizure frequency was −20.1% for placebo vs −42.6%, −77.1%, and −89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure‐free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12‐week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment‐emergent adverse events in cenobamate patients (≥20%) were dose‐related dizziness and somnolence. Significance Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose‐related fashion and was generally well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National University College of Medicine, Seoul, Republic of Korea.
- Huashan Hospital, Fudan University, Shanghai, China.
- SK Biopharmaceuticals Co., Ltd., Seongnam, Republic of Korea.
- SK Life Science, Inc., Paramus, New Jersey, USA.
- Yonsei University College of Medicine, Seoul, Republic of Korea.
- Epilepsy & Sleep Center, St. Peter's General Hospital, Seoul, Republic of Korea.
ORCID-Profile: Sang Kun Lee, Peimin Yu, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Zhen Hong, Koji Iida, Yong Heui Jeon, Kensuke Kawai, Ji Hyun Kim, Xiaorong Liu, Jungshin Park, William E Rosenfeld, Takamichi Yamamoto, Dong Zhou, Suiqiang Zhu, Sunita N Misra
Förderung
- SK Biopharmaceuticals
- SK Life Science
Zitieren
APA
Lee, S. K., Yu, P., Choe, E., Ferrari, L., Heo, K., Hong, S. B., Hong, Z., Iida, K., Jeon, Y. H., Jung, J., Kamin, M., Kawai, K., Kim, J. H., Kim, M. W., Liu, X., Park, J., Rosenfeld, W. E., Yamamoto, T., Zhou, D., …, & Misra, S. N. (2026). A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures. Epilepsia, 67(2), 660-672. https://doi.org/10.1111/epi.18698
Vancouver
Lee SK, Yu P, Choe E, Ferrari L, Heo K, Hong SB, et al. A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures. Epilepsia. 2026;67(2):660-672. doi:10.1111/epi.18698
BibTeX
@article{Lee2026,
author = {Lee, Sang Kun and Yu, Peimin and Choe, Eunyeong and Ferrari, Louis and Heo, Kyoung and Hong, Seung Bong and Hong, Zhen and Iida, Koji and Jeon, Yong Heui and Jung, Jiwon and Kamin, Marc and Kawai, Kensuke and Kim, Ji Hyun and Kim, Myung Won and Liu, Xiaorong and Park, Jungshin and Rosenfeld, William E and Yamamoto, Takamichi and Zhou, Dong and Zhu, Suiqiang and Misra, Sunita N},
title = {A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures},
journal = {Epilepsia},
year = {2026},
volume = {67},
number = {2},
pages = {660--672},
doi = {10.1111/epi.18698}
}
EUVIMED